Absci (NASDAQ:ABSI) Issues Quarterly Earnings Results

Absci (NASDAQ:ABSI) announced its quarterly earnings data on Thursday. The company reported ($0.19) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.19), FiscalAI reports. The firm had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.66 million. Absci had a negative return on equity of 61.71% and a negative net margin of 7,756.38%.

Here are the key takeaways from Absci’s conference call:

• Absci expects to report interim 13-week pattern hair loss data in December 2026 and full 26-week proof-of-concept data in early 2027. Management characterized the interim readout as directional and said it will not change the ongoing trial.
• The company said blinded aggregate data to date show ABS-201 is well tolerated, and its estimated half-life may support two or three injections over six months. These findings are preliminary and do not yet establish efficacy.
• Absci now anticipates starting its planned phase II endometriosis trial in mid-2027, with doses to be selected after reviewing HEADLINE trial data. The company estimates the program could reach more than $4 billion in peak sales if development succeeds.
• Cash, cash equivalents and marketable securities totaled $173.7 million at quarter-end, down from $201.1 million at June 30; management expects funding to last into the second half of 2028. Quarterly R&D expenses rose to $23.6 million from $19.2 million a year earlier, while SG&A increased to $9 million from $8.4 million.
• Management cited consumer research suggesting that 30–35 additional target-area hairs per square centimeter at 26 weeks could support strong adoption, and estimated a $25 billion U.S. pattern hair loss market. These are company estimates based on hypothetical product profiles, not clinical results.

Absci Stock Performance

Shares of ABSI traded down $0.50 during mid-day trading on Thursday, hitting $9.62. 3,327,155 shares of the company traded hands, compared to its average volume of 4,308,760. The stock has a 50-day moving average price of $9.65 and a two-hundred day moving average price of $6.75. Absci has a 1 year low of $2.24 and a 1 year high of $12.54. The stock has a market cap of $1.65 billion, a price-to-earnings ratio of -12.12 and a beta of 2.22.

Key Stories Impacting Absci

These are some of the ABSI stories that stood out recently:

• Positive Sentiment: Absci said its Phase 2 HEADLINE trial of ABS-201 for pattern hair loss remains on track, with 13-week proof-of-concept data expected in December 2026 and 26-week results expected in early 2027. The data could be an important clinical catalyst. Absci reports business updates and third-quarter results
• Positive Sentiment: The company reported $173.7 million in cash, cash equivalents and marketable securities, which it expects to fund operations into the second half of 2028. It also plans to start a Phase 2 ABS-201 trial for endometriosis in mid-2027. Absci reports third-quarter loss as ABS-201 trial advances
• Neutral Sentiment: Absci appointed Gerry Muhle, a former Galderma executive with experience launching prescription biologics, as chief commercial officer. The hire adds commercial expertise, though its impact depends on future pipeline progress. Absci appoints Gerry Muhle as chief commercial officer

Analyst Upgrades and Downgrades

Several analysts have commented on ABSI shares. KeyCorp raised their price objective on shares of Absci from $16.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, October 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Absci in a report on Thursday, October 15th. Lifesci Capital started coverage on shares of Absci in a research report on Wednesday, September 9th. They issued an “outperform” rating on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Absci in a research report on Tuesday, October 20th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Absci in a research note on Wednesday, September 23rd. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.50.

About Absci

Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines. The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.